PDL BioPharma, Inc. reaches settlement

PDL BioPharma, Inc., of incline Village, has entered into a settlement agreement with Valeant Pharmaceuticals International, Inc. and its indirect subsidiary Valeant Pharmaceuticals Luxembourg S.à r.l.

The lawsuit was filed on Sept. 7 and relating to alleged underpayment of royalties by Valeant. Under the settlement, Valeant will pay a lump sum of $13 million and release all claims against it.

In another announcement, Neos Therapeutics, Inc., has rejected PDL BioPharma’s offer to acquire Neos.

On Oct. 26, PDL proposed to acquire Neos for $10.25 per share in cash.


Use the comment form below to begin a discussion about this content.

Sign in to comment